The effects of COVID-19 on IBD prescribing and service provision in a UK tertiary centre.

Esha Sharma Susanna MeadeFrancesca D'ErricoPolychronis PavlidisRaphael LuberSebastian ZekiKatie HillAlexa DuffDearbhaile O'HanlonSherill TripoliAnna StantonAndra CaracosteaSailish HonapRebecca ReynoldsSimon AndersonShuvra RayJoel MawdsleyJeremy SandersonMark A SamaanPeter M Irving

Published in: GastroHep (2020)

We observed prescribing differences during COVID-19, bypassing the initiation of immunomodulators and/or anti-TNF therapy in favour of vedolizumab with a reduction in immunomodulator prescribing. We also observed a rapid reorganisation of service provision, including a shift towards telemedicine and online solutions.

Keyphrases

primary care
mental health
healthcare
coronavirus disease
adverse drug
sars cov
palliative care
ulcerative colitis
rheumatoid arthritis
social media
health information
stem cells
cross sectional
bone marrow
respiratory syndrome coronavirus
drug induced